Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.
Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
Int J Mol Sci. 2022 Dec 3;23(23):15272. doi: 10.3390/ijms232315272.
Huntington's disease (HD) is an autosomal dominant neurodegenerative disease that occurs worldwide. Despite some progress in understanding the onset of HD, drugs that block or delay symptoms are still not available. In recent years, many treatments have been proposed; among them, nuclear transcriptional factor-2 (Nrf2) enhancer compounds have been proposed as potential therapeutic agents to treat HD. Nrf2 triggers an endogenous antioxidant pathway activated in different neurodegenerative disorders. Probably, the stimulation of Nrf2 during either the early phase or before HD symptoms' onset, could slow or prevent striatum degeneration. In this review, we present the scientific literature supporting the role of Nrf2 in HD and the potential prophylactic and therapeutic role of this compound.
亨廷顿病（HD）是一种常染色体显性神经退行性疾病，在全球范围内都有发生。尽管在了解 HD 的发病机制方面取得了一些进展，但仍没有能够阻止或延缓症状的药物。近年来，提出了许多治疗方法；其中，核转录因子-2（Nrf2）增强化合物被提议作为治疗 HD 的潜在治疗剂。Nrf2 触发不同神经退行性疾病中激活的内源性抗氧化途径。可能，在 HD 症状出现之前或早期刺激 Nrf2，可以减缓或防止纹状体退化。在这篇综述中，我们介绍了支持 Nrf2 在 HD 中的作用以及该化合物的潜在预防和治疗作用的科学文献。
